CASE PD/4-32616A



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

FU 483 669057US

FULLY

Puly 15 DOUS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF LEDERGERBER ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2003/008999

FILED: 13 AUGUST 2003

U.S. APPLICATION NO: 10/523,750

35 USC §371 DATE: 8 FEBRUARY 2005

FOR: TOPICAL ANHYDROUS AND ETHANOL-FREE ASCOMYCIN

COMPOSITIONS

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed February 8, 2005. Since Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

1615

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Gregory ... Houghton

Reg. No. 47,666

Attorney for Applicants

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-2614

Date: 7/18/05

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. PD/4-32616A APPLICATION NO. 10/523,750 APPLICANT LEDERGERBER ET AL. FILING DATE FEBRUARY 8, 2005

Group

JUL 1 8 2005 5

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	,	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
-	AA	5,385,907	1/31/95	Asakura et al.	514	291	5/17/93
	AB	5,932,243	8/3/99	Fricker et al.	424	450	8/22/97
	AC	5,939,427	8/17/99	Kagayama et al.	514	291	1/5/98
	AD	2001/0051650	12/13/01	Kriwet et al.	514	411	5/31/01
	AE						
	AF						
	AG						
	АН			- 1 11 11			
	Al						
	AJ						
_	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	АМ	4 418 115	12/1/94	DE (Abstract)				
-	AN	0 423 714	4/24/91	EP				
	AO	0 474 126	3/11/92	EP				
	AP	0 753 297	1/15/97	EP				
	AQ	2 327 610	2/3/99	GB				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

A	ΑR	Meingassner et al., "Immunosuppressive Macrolides of the Type FK 506: A Novel Class of Topical Agents for Treatment of Skin Diseases?", J. Invest. Dermatol., Vol. 98, pp. 851-855 (1992).
А	AS	
А	ΑT	
EVALUED		DATE CONCIDEDED

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. PD/4-32616A APPLICATION NO. 10/523,750 APPLICANT LEDERGERBER ET AL. FILING DATE FEBRUARY 8, 2005

Group

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	BA	08-133979	5/28/96	JP (Abstract)				
	BB	10-251137	9/22/98	JP (Abstract)				
	ВС	94/28894	12/22/94	wo				
	BD	99/24036	5/20/99	wo				
	BE	99/55337	11/4/99	wo				
	BF	00/32234	6/8/00	wo				
	BG	02/080978	10/17/02	wo				
	вн	02/096419	12/5/02	wo				
	ВІ							
	BJ							
	вк							
	BL							
	вм		·					
	BN							
	во							
	BP							
	BQ					,		
	BR							
	BS							
	вт		•					
	BU					·		
	BV							
	BW							
	вх							
	BY		-					
EXAMINI	BZ			DATE CONSIDERED				

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.